Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_sessionnr5erphtivqtfu1kbm0to7v7jg0sbckd): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Meniscal injuries are commonplace, but current surgical repair procedures do not prevent degenerative joint changes that occur after meniscal injury and often lead to osteoarthritis. Successful tissue regeneration in adults often recapitulates events that occur during embryogenesis, suggesting that understanding the regulatory pathways controlling these early processes may provide clues for developing strategies for tissue repair. While the mouse is now widely used to study joint diseases, detailed knowledge of the basic biology of murine meniscus is not readily available. Here, we examine meniscal morphogenesis in mice from embryonic day 13.5 (E13.5) to 6 months of age using histology, in situ hybridization, and immunohistochemistry. We find that the meniscus is a morphologically distinct structure at E16 when it begins to regionalize. At birth, the meniscus has a distinguishable inner, avascular, round chondrocyte cell region, an outer, vascularized, fibroblast cell region, and a surface superficial zone. Maturation begins at 2 weeks of age when the meniscus expresses type I collagen, type II collagen, type X collagen, and MMP-13 in specific patterns. By 4 weeks of age, small areas of ossification are detected in the anterior meniscal horn, a common feature seen in rodents. Maturation appears complete at 8 weeks of age, when the meniscus resembles the adult structure complete with ossifying tissue that contains bone marrow like areas. Our results provide, the first systematic study of mouse meniscal development and will be a valuable tool for analyzing murine models of knee joint formation and disease. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:1683-1689, 2017.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jor.23446 | DOI Listing |
Blood
March 2025
Sanofi, Cambridge, Massachusetts, United States.
Rilzabrutinib is a covalent, reversible BTK inhibitor with multiple mechanisms targeting key immune thrombocytopenia (ITP) disease pathophysiology. The phase 3 LUNA3 study in previously treated adults with persistent/chronic ITP evaluated oral rilzabrutinib 400 mg bid (n=133) vs placebo (n=69) for 24 weeks. At baseline overall, median age was 47 years (range, 18-80), 63% female, 7.
View Article and Find Full Text PDFEur J Med Res
March 2025
Department of Internal Medicine, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, 138 Sheng Li Road, Tainan, Taiwan.
Objective: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a standard therapy for patients who respond poorly to or cannot tolerate statins. However, identifying responders to PCSK9 inhibitors remains unclear. This study investigates the characteristics of patients who achieve target LDL-C reduction (< 70 mg/dl) after PCSK9 inhibitor therapy.
View Article and Find Full Text PDFSemin Perinatol
March 2025
Department of Obstetrics and Gynecology Herbert Wertheim College of Medicine, Florida International University Miami, FL, United States.
Objective: The objective of this manuscript is to review the epidemiology, diagnosis, treatment and outcomes of ovarian cancers diagnosed during pregnancy.
Finding: Ovarian cancer in pregnancy, although rare, is more likely to be diagnosed early during pregnancy due to the increased use of high resolution ultrasound. Treatment will depend on a multidisciplinary team.
J Pediatr
March 2025
Department of Paediatrics, Sinai Health, Toronto, Ontario, Canada; Department of Paediatrics and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Objective: To examine associations between enteral feed type with neurodevelopmental and neonatal outcomes among infants born preterm.
Study Design: This was a retrospective study of enteral feeds in the first 28 postnatal days in infants born <29 weeks' gestation from 2015 through 2020 in neonatal units of the Canadian Neonatal Network and Canadian Neonatal Follow-Up Network. Feeds were examined as a compositional variable comprised of the proportion of days fed mother's milk, donor milk, mixed feeds, and nil per os (NPO), the proportions of which sum to 1.
Am J Ophthalmol
March 2025
Genentech, Inc., South San Francisco, CA.
Purpose: To investigate the safety, tolerability, and efficacy of intravitreal injection of galegenimab, an anti-HtrA1 FAb, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Design: Phase 2, single-masked, randomized clinical trial.
Methods: Eligible GA patients with BCVA letter scores of ≥ 24 letters and baseline GA lesion size 2.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!